
Opinion|Videos|October 13, 2023
Updates in the Management of Lower-Risk MDS
Author(s)Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Dr Hans Lee on the Game-Changing Myeloma Research From ASH 2025
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
The Targeted Pulse: Blood and Breast Cancer News
5














































